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A bstract
Herpes virus entry m ediator (HVEM) is a newly  
discovered m em ber of the tum or necrosis factor 
receptor (TNFR) superfam ily that has a role in  
herpes sim plex virus entry, in T cell activation and  
in tum or im m unity. W e generated m Ab against 
HVEM and detected soluble HVEM (SHVEM) in the  
sera of patients with various autoim mune diseases. 
HVEM was constitutively expressed on CD4+ and  
CD8+ T cells, CD19+ B cells, CD14+ m onocytes, 
neutrophils and dendritic cells. In three-way MLR, 
m Ab 122 and 139 were agonists and m Ab 108 had  
blocking activity. An ELISA was developed to detect 
sHVEM in patient sera. sHVEM levels were elevated  
in sera of patients w ith allergic asthm a, atopic  
derm atitis and rheum atoid arthritis. The m Abs dis -
cussed here m ay be useful for studies of the role  
of HVEM in immune responses. Detection of soluble  
HVEM m ight have diagnostic and prognostic value  
in certain im m unological disorders. 
Keywords: asthma; atopic; autoimmune diseases; der-
matitis; inflammation mediators; rheumatoid arthritis; 
tumor necrosis factor
In troduction
M embers of the tum or necrosis factor receptor 
(TNFR) superfamily share a similar architecture of 
their extracellular domain; this consists of a series of 
cysteine-rich segments containing 30-40 amino acids 
with six cysteines in each segment (Mallett et al., 
1991). They are involved in the regulation of diverse 
immune functions. Some of the members of this 
family regulate signals leading to apoptosis, whereas 
others are involved in lymphocyte activation and 
differentiation (Locksley et al., 2001; Kwon et al., 
2003). The open reading frame of herpes virus entry 
mediator (HVEM) encodes a 283 amino acid sequence, 
two perfect TNFR-like cysteine-rich domains, two im-
perfect cysteine-rich domains, and a short cytoplasmic 
tail similar to that seen in 4-1BB and CD40 (Mont-
gomery et al., 1996; Kwon et al., 1997). Because an 
HVEM-Fc fusion protein inhibited proliferation in a 
mixed lymphocyte reaction using patient lymphocytes 
(Harrop et al., 1998), HVEM may either play a direct 
role in T cell stimulation or bind to a ligand that 
stimulates T cell proliferation. HVEM is a cellular 
mediator of the entry of herpes simplex virus type-1 
(HSV-1) (Montgomery et al., 1996) and interacts 
directly with the HSV virion glycoprotein D (gD) 
required for entry into HVEM expressing cells (Whit-
beck et al., 1997). Hsu et al. (1997) found that the 
cytoplasmic region of HVEM binds to several mem-
bers of the TNFR-associated factor (TRAF) family, 
namely, TRAF1, TRAF2, TRAF3, and TRAF5, but not 
to TNFR4 or TRAF6, and that it activates transcription 
factors NF-κB and AP-1 (Marsters et al., 1997). As 
anti-HVEM mAb are needed for or in-depth studies 
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of the role of HVEM in immune responses and in 
clinical settings, we generated several mAbs and 
used them to characterize HVEM, and to detect 
soluble HVEM in clinical samples. 
M ateria ls and M ethods
C ells and cell culture
Monocyte-like cell lines HL-60, U937, and THP-1, 
human CD4+ T cell lines Jurkat and PM-1, human 
embryonic kidney cell line 293, and SP2/0 myeloma 
cell line were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA). They were 
cultured in either RPMI 1640 or DMEM, supplemented 
with 10% FBS (Hyclone) and antibiotics. Growth was 
at 37oC with 5% CO2/air. 
Expression and purification of recom binant 
H VEM -G ST and H VEM -Fc fusion proteins
We used PCR to amplify the cDNA sequence that 
encodes the ectodomain of HVEM. It was fused in 
frame with the GST-binding domain of glutathionine 
S-transferase (GST) or with human IgG1 Fc (including 
hinge, CH2 and CH3 domains). Each of the in-frame 
fusions was confirmed by sequencing before being 
cloned into the PGEX-3 or pcDNA3 expression vector. 
pGEX-3-HVEM-transformed Escherichia coli were 
grown to an optical density of 0.6 (A590) before protein 
expression was induced by the addition of 2 mM (final 
concentration) isopropyl thiogalactopyranoside (IPTG). 
The HVEM-GST fusion protein was purified by two- 
step chromatography with GSH-sepharose 4B. HVEM- 
Fc fusion protein was produced in NIH 3T3 cells and 
purified with a protein G column. An automatic 
peptide sequencer (ABI, Perkin-Elmer, Norwalk) was 
used to determine N-terminal amino acid sequences.
Im m unization  and fusion  
A 6-8 week-old female Balb/c mouse (Harlan, India-
napolis, IN) was injected i.p. with 30 µg HVEM-GST 
fusion protein emulsified with an equal volume of 
Freund's complete adjuvant (Gibco-BRL, Gaithersburg, 
MD). After two weeks the mouse was injected IP with 
the same amount of HVEM-GST fusion protein emul-
sified with an equal volume of Freund's incomplete 
adjuvant. Two weeks later the mice received a third 
injection i.v. of 30 µg of HVEM-GST in PBS. Fusion 
of myeloma cells with splenocytes was performed as 
described by Kohler and Milstein (1975). SP2/0 were 
used as fusion partner during exponential growth, with 
more than 95% viability. Primed lymphocytes were 
mixed with myeloma cells at a ratio of 5:1 and fused 
in 50% (w/v) polyethylene glycol MW 1500 (Boeh-
ringer Mannheim, Indianapolis, IN). Cells were se-
lected in HAT medium (Boehringer Manheim) using 
peritoneal macrophages as feeder cells. Antibody 
activity was determined after 10-14 days. 
ELISA  screening
We determined the anti-HVEM activity of supernatants 
of the hybridoma cells by ELISA (Jin et al., 2001). 
ninety-six-well polypropylene microplates (Falcon, 
Oxnard, CA) were coated with 5 mg/ml HVEM-Fc in 
NaHCO3 overnight at 4oC, blocked with 3% BSA, and 
incubated with the supernatants. Goat anti-mouse IgG 
conjugated with horseradish peroxidase (Sigma, St. 
Louis, CA) was used as secondary antibody. Plates 
were washed five times with PBS/Tween-20 before 
detecting bound antibody by incubation with ABT 
peroxidase substrate (Kirkegaard and Perry Lab, Inc., 
Gaithersburg, MD). Serum obtained from the mouse 
used to provide the splenocytes was used as a 
positive control. The Ig class and subclass of the 
resulting monoclonal antibodies was determined with 
the ImmunoPure Monoclonal Antibody Isotyping Kit 
(Pierce, Rockford, IL). 
Purification of m onoclonal antibodies
Balb/c mice were primed with Pristane and injected 
IP with subcloned hybridoma cells to induce ascites 
formation. The mAbs were purified from the ascites 
fluid by affinity column chromatography with protein 
G-Sepharose (Zymed Lab, Inc, South San Francisco, 
CA) (Coligan et al., 1991). The three monoclonal 
antibodies (mAbs) used in this work, clones 108, 122 
and 139, were of isotypes IgG1 (colnes, 108 and 122) 
or IgG2a (clone 139).
SD S-PA G E and W estern b lot analysis
HVEM-GST was purified by two-step chromatography 
with GST-sepharose 4B, and used as control for 
Western blot analysis. Lysates (5×107 cells/ml) of 
THP-1 and Jurkat cells were digested in lysis buffer 
[1% Triton X-100 in 150 mM NaCl and 20 mM 
Tris-HCl (pH 8.0)] at 4oC for 30 min. The lysates and 
HVEM-GST were denatured by boiling for 5 min with 
0.5% SDS and 1% β-mercaptoethanol, subjected to 
SDS-PAGE, and transferred to nitrocellulose mem-
branes. The membranes were blocked in reaction 
buffer (10 mM Tris [pH 7.4], 150 mM NaCl, 10% 
nonfat dried milk, 0.05% Tween-20) for 1 h and 
incubated with anti-HVEM mAb 108 diluted 1:5,000 in 
reaction buffer, followed by horse peroxidase-coupled 
goat anti-mouse IgG (Boehringer Mannheim) diluted 
1:10,000. Secondary antibody was detected by in-
cubation in ECL reagent (Amersham Biosciences, 
Piscataway, NJ) and exposure to X-ray film (Kodak, 
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Rochester, NY).
Flow  cytom etry  
293 cells transfected with HVEM-pcDNA3 were stained 
48 h after transfection. Cultured cells were also 
stained with or without stimulation with anti-CD3 
(OKT3; 1 µg/ml) and LPS (100 ng/ml). They were 
washed twice, resuspended in 1% paraformaldehyde 
and analyzed by flow-cytometry with a FACScan 
(Becton Dickinson, San Jose, CA). Human PBMC 
were isolated from healthy donors by Ficoll-Paque 
Plus (Amersham Pharmacia, Oakville, Canada) at 300 
g for 30 min. Neutrophils were isolated by poly-
morphprep (Nycomed Pharma AS, Oslo, Norway) gra-
dient centrifugation according to the manufacturer's 
protocol. PBMC and neutrophils were washed in 
complete culture media. FITC-conjugated anti-HVEM 
mAb 122, PE-conjugated anti-CD4, CD8, CD19, and 
CD14 mAbs (BD PharMingen, San Diego, CA) were 
used to detect PBMC that expressed HVEM. Isotype- 
matched antibodies were used as controls. 
D endritic cell m aturation
Dendritic cells (DC) were prepared from monocytes 
of PBMC as previously described (Brown et al., 
2003). To obtain monocytes, non-adherent cells were 
removed following 2 h incubation at 37oC, and adher-
ent cells scraped off culture dishes. The monocytes 
were further enriched by incubation with anti-CD14 
magnetic beads (Miltenyi Biotec., Bergisch Gladbach, 
Germany). They were cultured in 6-well plates at 2×
106 cells/well with GM-CSF (800 U/ml) and IL-4 
(1,000 U/ml) for 6 days. Maturation of immature DCs 
(iDCs) was accomplished by transferring the cells to 
new 6-well plates and supplementating with mono-
cyte- conditioned medium and TNF-α at final concen-
trations of 20% vol/vol and 10 ng/ml, respectively. 
Fresh GM-CSF and IL-4 were present throughout 
growth. The mature DCs (mDCs) were consistently 
made up of 90-95% CD11c+ cells. 
M LR -m ediated PB M C  proliferation
PBMC were isolated from three healthy adult volun-
teers by Ficoll gradient centrifugation at 400×g for 
30 min. They were recovered, washed in RPMI 1640 
(Life Technologies, Gaithersburg, MD) supplemented 
with 10% fetal bovine serum and antibiotics, and 
adjusted to 1×106 cells/ml in the case of two of the 
donors, and to 2×105 cells/ml in the third. Fifty µl 
of each cell suspension was added to a 96-well 
(round bottom) plate (Falcon, Franklin Lakes, NJ) 
together with 50 ul of mAb 108, 122, 139 or unrelated 
control mAb. The plates were incubated at 37oC in 
5% CO2 for 96 h. One µCi of [3H]methylthymidine 
(ICN Biomedicals, Costa Mesa, CA) was then added 
for an additional 16 h. The cells were harvested, and 
radioactivity counted.
Detection of soluble HVEM (sHVEM) in human serum  
sHVEM was detected by ELISA using 108 as cap-
turing mAb, and 122 as detecting mAb. A standard 
curve was constructed with HVEM-Fc (R & D system, 
Minneapolis, MN) as antigen. The ELISA plate was 
coated with 100 µg per well of mAb 108 (1 µg/ml), 
and blocked with 200 µg/well of 4% BSA. Samples 
of 100 µg/well were added, incubated at 37oC for 1 
h and washed. Biotin-labeled mAb 122 was then 
added and incubation continued for another 1 h at 
37oC. The plate was washed and streptavidin-conju-
gated horse-radish peroxidase added. TMB substrate 
solution (Endogen, Pierce biotechnology, Rockford, 
CA) was introduced and absorbance at 450 nm mea-
sured. The standard curve constructed with HVEM-Fc 
indicated that the sensitivity limit was 16 pg/ml. All 
assays were performed blind, and at the same time, 
on coded sterile samples.
Serum  sH VEM  data analysis
Comparisons of the sHVEM values of each patient 
and the healthy controls were assessed by one-way 
ANOVA. The statistical analyses were performed with 
the MicrocalTM OrijinTM software package (Microcal-
Software, Inc, Northampton, MA). A P-value of less 
than 0.05 was considered statistically significant.
R esu lts  
A nti-H VEM  m onoclonal antibodies
To produce mAbs that recognize HVEM, the HVEM- 
Fc fusion protein was used for ELISA screening since 
the HVEM-GST fusion protein had been used as 
immunogen. Specificity was confirmed by lack of 
cross-reaction with GST and other bacterial proteins. 
Flow cytometry was used to identify mAbs that 
stained native cell surface HVEM so that the mAbs 
could be used in future studies of the functions of 
HVEM in human immune system. Positive clones 
were subcloned at least twice by limiting dilution. The 
ELISA ImmunoPure Monoclonal Antibody Isotyping Kit 
showed that mAb 122 and 108 were IgG1 subclass 
antibodies and mAb 139 was an IgG2a subclass 
antibody.
Specific ity  o f anti-H VEM
To determine the specificity of the anti-HVEM mAbs, 
the hybridoma cell culture supernatants were used to
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stain 293 cells transfected with either sense or anti-
sense HVEM cDNA. Goat anti-mouse-FITC conju-
gated antibody was used as secondary antibody. Flow 
cytometric analysis showed that all three selected 
mAbs recognized sense but not anti-sense HVEM. 
This indicates that all three mAbs are specific for 
surface expressed HVEM (Figure 1). The slight differ-
ence between the three mAbs in staining efficiency may 
result from: 1) different binding affinities, 2) recognition 
of different HVEM epitopes, or 3) different concentra-
tions in the culture supernatants. Anti-HVEM mAbs 122, 
108 and 139 recognized different epitopes on HVEM 
since they did not compete for Ag (data not shown), 
and therefore were used in ELISAs for sHVEM.
  The specificity of the mAbs was further analyzed 
by Western blot analyses with mAb 108 from cell 
F ig u re  1 . Binding of mAbs to 293 cells transfected with HVEM PcDNA3. 293 cells, transiently transfected with sense (heavy lines) or antisense
(thin lines) HVEM pcDNA3 for 48 h, were incubated with hybridoma culture supernatants followed by FITC-conjugated goat anti-mouse IgG and





















F ig u re  2 . W estern blot analysis of HVEM. Cell lysates and HVEM- 
GST samples were separated by SDS-PAGE, and analyzed by 
Western blotting with mAh108. Lane M; protein size markers, lane 1,
THP-1 cells; lane 2, Jurkat cells; lane 3, HVEM-GST (0.2 µg/well);
lane 4, GST. Arrow indicates HVEM.
F ig u re  3 . HVEM expression and distribution on human peripheral blood mononuclear cells detected with mAb 122. Human PBMC were isolated
from healthy adult volunteers as described in Materials and Methods, and incubated with mIgG1 (filled peaks) or mAb 122 (clear peaks), followed
by FITC-conjugated goat anti-mouse IgG. In addition, the PBMC were subjected to a second color fluorescence with Tric-conjugated anti-CD4,
CD8, CD14 or CD19 mAbs. Analysis was performed with a FACscan.
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lysates and HVEM-GST to detect protein fragments 
(Figure 2). Lysates from intact cells showed a major 
band at 40.0 kDa with some smaller fragments between 
32.0 and 39.0 kDa (Figure 2, lane 1 and 2). HVEM- 
GST gave a single band of 42.2 kDa recognized by 
the anti-HVEM (Figure 2, lane 3). Thus, it is likely that 
natural form of HVEM is 40.0 kDa glycoprotein.
H VEM  expression  
Immunostaining with mAb 122 (mIgG1) yielded gener-
ally the highest intensity of staining and the lowest 
non-specific background. Flow cytometric analysis of 
human PBMC using two color analysis, showed that 
HVEM was constitutively expressed on CD3+ T lym-
phocytes, including both CD4+ and CD8+ subsets, and 
was also highly expressed on CD19+ B lymphocytes, 
CD14+ monocytes and neutrophils (Figure 3). Expres-
sion on T cells increased marginally after 24 h stimu-
lation. As previously shown [5], freshly isolated 
peripheral T cells expressed high levels of HVEM. 
When cells were activated for 3 days, expression 
decreased slightly (data not shown). HVEM may be 
constitutively expressed in T cells in the absence of 
stimulation.
  The expression pattern of HVEM was investigated 
on myeloid cells such as dendritic cells (DCs). HVEM 
was constitutively expressed at a high level on 
peripheral monocyte-derived immature DCs (Figure 4). 
Expression barely changed after maturation with an 
inflammatory cytokine such as TNF-α (Figure 4A). 
Expression was also detected on CD34+ DCs derived 
from cord blood cells (Figure 4B), but activation of 
these mature DCs with LPS had little effect on 
expression (data not shown). 
Effect of anti-H VEM  m A bs on M LR  
proliferation responses
In order to examine the stimulatory or inhibitory ca-
pacity of the mAbs, their effect on a three-way mixed 
leukocyte reaction (MLR) were tested. As shown in 
Figure 5, mAb 122 strongly enhanced PBMC prolif-
eration; mAb 139 also had a stimulatory effect, where-
as mAb 108 blocked the MLR-mediated PBMC pro-
liferation. We conclude that 122 and 139 are agonistic 
mAbs, and 108 is an antagonistic mAb.
sH VEM  in  hum an serum
Apart from some decoy receptors, molecules of the 
TNF receptor superfamily are cell surface molecules. 
However, they can be cleaved from the cell mem-
brane in some clinical situations, generating soluble 
derivatives. We investigated sHVEM levels in sera 
from healthy donors, and patients with certain immu-
nological diseases (atopic dermatitis; AD, psoriasis;
F ig u re  4 . HVEM expression on monocytes, iDC and mDC. DC were
prepared from PBMC (A), or from cord blood CD34+ cells (B) as 
described in Materials and Methods. iDC were harvested on day 5
of culture and incubated for an additional 2 days with TNF-α , to 
produce mDC. DC were stained with anti-CD11c-PE and anti-HVEM- 
FITC and analyzed by flow cytometry. HVEM was detected by mAb122
(heavy lines or by control IgG 1 (light line) in (A). Shigted heavy 
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PSO, allergic asthma; AA, rheumatoid arthritis; RA, 
systemic lupus erythematosus; SLE, Bechet's disease; 
BD) and with pneumonia (P) and lung cancer (LC) 
using a sandwich ELISA technique (Figure 6).
  sHVEM was significantly elevated in sera of 
patients with AD (mean±SD; 718±617 pg/ml; P＜ 
0.01), with AA (871±712 pg/ml; P＜0.001), with RA 
(1638±1366 pg/ml; P＜0.001), with SLE (544±395 
pg/ml; P＜0.05), with BD (755±790 pg/ml; P＜0.05), 
and with pneumonia (808±557 pg/ml; P＜0.05) 
compared with those of healthy controls (304±184 
pg/ml). Sera from patients with LC had very low levels 
(100±57 pg/ml) of sHVEM. Thus our data indicate 
that significantly higher levels of sHVEM are present 
in sera of patients with immunological disorders such 
as AA, and RA than in healthy control. Although AD 
and SLE show a trend of high serum concentration 
of sHVEM, a conclusion can not be drawn because 
of small sample size.
D iscussion
Earlier study showed that HVEM expression at the 
mRNA level was most prominent in lymphoid tissues 
such as thymus, spleen and peripheral blood leuko-
cytes (PBLs), although it had a wide tissue distribu-
tion; HVEM mRNA was also abundant in both resting 
and activated CD4+ and CD8+ T cells, CD19+ B cells, 
and monocytes (Kwon et al., 1997). Consistent with 
those results, present study confirmed that there is 
cell surface expression of HVEM on primary T cells, 
B cells and monocytes. In addition, HVEM was 
detected on other immune cells such as neutrophils, 
monocytes and CD34+ cord blood cell-derived DCs. 
This indicates that HVEM is widely expressed on 
immune cells and is not restricted to any subpopu-
lations of PBLs. This wide distribution seems to be 
unique to HVEM, since expression of most TNF 
receptor superfamily members is restricted to partic-
ular immune cells (Gruss, 1996; Lotz et al., 1996). 
The expression pattern of HVEM suggests that it may 
play a role in multiple aspects of the immune re-
sponse. Since the expression of LIGHT (the HVEM 
ligand) on T cells is induced after activation, T cell 
activation through HVEM signaling may involve 
interaction of T cells with each other. Indeed, block-
ade of HVEM-LIGHT interactions inhibits proliferation 
of highly purified T cells in response to TCR stimu-
lation (Shaikh et al., 2001). Thus, co-stimulation via 
HVEM depends on the presence of LIGHT on T cells 
(Morel et al., 2000; Scheu et al., 2002). Interestingly, 
Morel et al. (2002) have provided evidence that 
HVEM expression is down-regulated by stimulation of 
LIGHT on activated T cells, suggesting that the 
HVEM-LIGHT system is self-regulating (Morel et al., 
2002). In sum, co-stimulation of T cells via HVEM 
signaling is likely to be reinforced by LIGHT expres-
sion following TCR engagement, and turned off after 
down-regulation of cell surface HVEM by LIGHT.
  At present, it is not known what function HVEM 
Figure 5 . Effect of mAbs on a mixed leukocyte reaction (MLR). PBMC
from two donors were adjusted to 1×106 cells/ml. Fifty m icroliters of
each cell suspension was added in quadruplicate to 96-well round 
bottom plates, together with 4  µ g/well of anti-HVEM mAb or control
mAbs. Total volume of each well was adjusted to 200  µ l/well. The
plate was incubated for 3 days and [3H]thymidine was added to each
well for an additional 12 h. The three anti-HVEM mAbs 122 (IgG 1),
108 (IgG 1) and 139 (IgG 2a) were used. mIgG 1 and mIgG 2a are Ig 
isotype controls. [3H]thymidine incorporation was measured as an 


























F ig u re  6 . Soluble HVEM (sHVEM) levels in sera of patients and 
healthy donors determined by ELISA. The data are means of 
triplicates, and horizontal bars depict means. ***P＜0.001, **P＜0.01,
and *P＜0.05 compared with the control group. HC, healthy controls;
AD, atopic dermatitis; PSO, psoriasis; AA, allergic asthma; RA, 
rheumatoid arthritis; SLE, systemic lupus erythematosus; BD, Bechet's
disease; P, pneumonia; LC, lung cancer, and N, number of donors
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has on B cells. Data presented here, and elsewhere, 
show that B cells express high levels of HVEM, 
suggesting that it may be involved in B cell function 
(Harrop et al., 1998). Since LIGHT is expressed on 
activated T cells, and transgenic mice that express 
LIGHT in their T cell lineage produce elevated levels 
of auto-antibodies (showing a systemic lupus erythe-
matosus phenotype), HVEM signaling on B cells may 
play a role in antibody production (Wang et al., 2001). 
The HVEM-LIGHT system could influence antibody 
production in two ways. First, the engagement of 
HVEM by LIGHT on activated T cells might enhance 
B cell activities. Second, stimulation of DC HVEM by 
LIGHT on activated T cells might activate DCs such 
that they in turn enhance B cell functions. 
  The expression and distribution of HVEM on vari-
ous established cell lines varied according to the 
proportion of cells used and their state of activation. 
It was constitutively expressed on the monocyte-like 
cell lines THP-1 and U937, whereas only very low 
levels were found on HL-60, human CD4+ T cells, 
Jurkat cells, PM-1, and the B-cell line Frev. Ex-
pression on HL-60, THP-1, U937, and Jurkat cells 
was significantly increased after 3 days stimulation 
with PMA (unpublished observation). Expression 
pattern of HVEM protein was similar to the mRNA 
expression data previously published by our labora-
tories (Lee et al., 2001) but there were differences 
in expression level that might be due to: 1) post-
translational modification, 2) configuration and pre-
sentation of epitopes recognized by the mAbs, 3) 
mAb sensitivity.
  The effect of the anti-HVEM monoclonal antibodies 
was examined in a mixed lymphocyte reaction (MLR). 
As shown in Figure 5, mAb 122 was stimulatory and 
mAb 108 inhibitory. MAb 139 was also stimulatory 
although less than mAb 122. These data can be 
interpreted as that HVEM and HVEM ligand are 
involved in cell-cell interaction in the MRL reaction 
and that an anti-HVEM mAb can behave in two 
different ways: MAb 122 and mAb 139 may be sig-
naling mAbs that can activate lymphocytes by cross- 
linking HVEM, whereas mAb 108 is a blocking mAb 
which binds to HVEM but does not generate a signal. 
These monoclonal antibodies will be useful in de-
termining the role of HVEM in T cell co-stimulation. 
  Processes mediated by members of the TNF 
receptor superfamily can be modified by proteolytic 
cleavage and shedding of cell surface TNF receptors. 
It is thought that soluble TNF receptors can compete 
with surface forms of the receptors, thereby de-
creasing the efficacy of their ligands (Salih et al., 
2001). This may affect cell-cell interactions and re-
sponses to receptor ligands, or it may provoke more 
distal responses to cellular activation (McGeehan et 
al., 1994). This study showed that considerable 
amounts of soluble HVEM exist in sera of patients 
with certain diseases, and that it is significantly 
elevated in patients with allergic diseases (atopic 
dermatitis and allergic asthma), autoimmune disease 
(rheumatoid arthritis), and inflammatory disease (pne-
umonia). According to previous reports (Cheng et al., 
1994; Michel et al., 1998; Schneider et al., 1998), 
there are high levels of soluble (s) Fas (sFas) and 
s4-1BB in sera of patients with multiple sclerosis and 
rheumatoid arthritis. The functions of sHVEM are not 
known but the present study suggests a more specific 
role in certain diseases. It will be important to 
determine whether the level of sHVEM in patient 
serum is correlated with progress and outcome of the 
disease (Sharief, 2002).
  In sum, this study demonstrated HVEM expression 
in a variety of immune cells, including T cells, B cells, 
monocytes, neutrophils and DCs. Like other members 
of the TNF receptor superfamily, soluble HVEM exists 
in sera of patients with immunological disorders. The 
levels of sHVEM in the serum of lung cancer patients 
were even lower than that in the serum of normal 
controls. Lung cancer samples were employed as a 
disease control in this study. We therefore do not 
know whether the low serum level of sHVEM in lung 
cancer patients reflects any immunological signifi-
cance or immune competency of the patients. It 
certainly warrants further studies.
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